George Miguel
Psychiatry · Joliet, ILNPI 1174591010
Payments from drug & device makers
Across 124 payments — averaging $20.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$464
- Sunovion Pharmaceuticals Inc.$331
- Otsuka America Pharmaceutical, Inc.$329
- Johnson & Johnson$225
- Abiomed$217
- AbbVie$194
- plus $734 from 14 others
What the payments were for
- Food & beverage$2,47699%
- Education$181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $464 |
| Sunovion Pharmaceuticals Inc. | 19 | $331 |
| Otsuka America Pharmaceutical, Inc. | 17 | $329 |
| Johnson & Johnson | 13 | $225 |
| Abiomed | 2 | $217 |
| AbbVie(2 entities) | 6 | $194 |
| Vanda Pharmaceuticals Inc. | 13 | $190 |
| Lundbeck LLC | 8 | $131 |
| Alkermes, Inc. | 6 | $97 |
| Pfizer | 1 | $91 |
| Jazz Pharmaceuticals Inc. | 3 | $54 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $36 |
| Shire North American Group Inc | 2 | $33 |
| Merck | 1 | $22 |
| Astellas Pharma US Inc | 1 | $18 |
| Neurocrine Biosciences, Inc. | 1 | $15 |
| Ironshore Pharmaceuticals Inc. | 1 | $13 |
| Tepha Inc | 1 | $12 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
| Vertical Pharmaceuticals, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,495 in reported general payments places this provider in the 80th percentile of 1,344 psychiatry providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abilify MaintenaAripiprazole | 30 | $88,534 |
| Chlorpromazine Hcl | 97 | $21,541 |
| VraylarCariprazine Hcl | 11 | $16,297 |
| Clomipramine Hcl | 47 | $14,931 |
| Clozapine | 174 | $11,394 |
| Divalproex Sodium | 253 | $10,498 |
| Aripiprazole | 187 | $7,067 |
| Divalproex Sodium ErDivalproex Sodium | 174 | $6,612 |
| Naltrexone Hcl | 163 | $5,869 |
| Fluvoxamine Maleate | 120 | $4,745 |
| Quetiapine Fumarate | 372 | $4,018 |
| Medroxyprogesterone Acetate | 23 | $4,014 |
| Ziprasidone Hcl | 99 | $3,841 |
| Benztropine Mesylate | 361 | $3,805 |
| Risperidone | 521 | $3,053 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $329 | $88,53430 claims |
| AbbVieVraylar | $194 | $16,29711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,344 psychiatry providers in Illinois.
Other psychiatry in Joliet
- Cosme LozanoJoliet$687K
- Jeffrey RossNorthbrook$10.8M
- Yuhwen ChowChicago$8.5M
- Mark LermanNorthbrook$4.5M
- Danesh AlamWinfield$2.7M
- John ZajeckaSkokie$2.5M
- Riaz BaberNaperville$2.4M
- Michael GreenbaumLibertyville$2.2M
- Sandeep GaonkarNaperville$1.8M
- Jon GrantChicago$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.